Keywords: Type 2 diabetes, Market forecasts, Merck & Co, Januvia, AstraZeneca, Bristol-Myers, dapagliflozin, Johnson & Johnson, Canagliflozin, Decision Resources
Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021
Article | 16 October 2012
The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion in 2011 to nearly $50 billion in 2021 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
